Christine Yang

Christine Yang has extensive experience in program management within the biotechnology and pharmaceutical industries, currently serving as Executive Director, Program Management & Asset Lead at Tyra Biosciences from September 2023 to March 2025, where responsibilities include collaboration with Clinical Development leadership on strategic planning and lifecycle management for the TYRA-300 franchise. Prior roles include Senior Director of Program Management at Tyra Biosciences, where oversight included oncology and rare disease programs, and Director of Program Management at Allogene Therapeutics, focusing on alloCAR T programs. Christine Yang has also held positions at Bellicum Pharmaceuticals, BeiGene, and Agensys, contributing to significant projects related to oncology therapeutics and clinical development, demonstrating expertise in strategic planning, governance, and cross-functional team leadership across various therapeutic areas.